INSULIN-LIKE GROWTH-FACTORS IN BREAST AND PROSTATIC-CANCER

被引：7

作者：

HELLE, SI

LONNING, PE

机构：

[1] Dept. Therapeut. Oncol./Radiophysics, University of Bergen, Haukeland Hospital

来源：

关键词：

D O I：

10.1677/erc.0.0020153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IGF-I and IGF-II are both potent mitogens to breast and prostatic carcinoma cells. Evidence suggests that the disposition of IGF-I is different in patients suffering from advanced breast and prostatic carcinoma when compared with healthy controls. Steroid hormones and endocrine manipulation used in the treatment of breast and prostatic carcinomas may influence the plasma concentration of IGF-I and its binding proteins. However, due to the complex regulation of IGF bioavailability, it is difficult to evaluate the impact of alterations in IGFBPs. Further studies are warranted to evaluate the influence of hormone treatment on IGF-I, IGF-II and their binding protein in plasma and, in particular, in tumour tissue from patients suffering from breast and prostatic carcinomas. While most studies so far have evaluated the influence of short-term hormone therapy on the disposition of IGF-I, it would be of particular interest to look at the effect of long-term treatment, and to evaluate possible alterations in the IGF system in relation to the emergence of resistance to endocrine therapy.

引用

页码：153 / 169

页数：17

共 140 条

[91]

MacNeill F.A., Jacobs S., Lonning P.E., Powles T.J., Dowsett M., Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression, British Journal of Cancer, 69, pp. 1171-1175, (1994)

[92]

Manni A., Boucher A.E., Demers L.M., Harvey H.A., Lipton A., Simmonds M.A., Bartholomew M., Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer, Breast Cancer Research and Treatment, 14, pp. 289-298, (1989)

[93]

Manni A., Wei L., Badger B., Zaenglein A., Leighton J., Shimazaki S., Ling N., Expression of messenger RNA for insulin-like growth factors and insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in vivo, Endocrinology, 130, pp. 1744-1746, (1992)

[94]

Manni A., Badger B., Wei L., Zaenglein A., Grove R., Khin S., Heitjan D., Shimasaki S., Ling N., Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: Evidence for stromal epithelial interactions, Cancer Research, 54, pp. 2934-2942, (1994)

[95]

Mansfield M.J., Rudlin C.R., Crigler J.F., Karol K.A., Crawford J.D., Boepple P.A., Crowley W.F., Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty, Journal of Clinical Endocrinology and Metabolism, 66, pp. 3-9, (1988)

[96]

Mathieu M., Rochefort H., Barenton B., Prebois C., Vignon F., Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/ mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II, Molecular Endocrinology, 4, pp. 1327-1335, (1990)

[97]

Meyer W.J., Furlanetto R.W., Walker P.A., The effect of sex steroids on radioimmunoassayable plasma somatomedin C concentrations, Journal of Clinical Endocrinology and Metabolism, 55, pp. 1184-1187, (1982)

[98]

Miell J.P., Taylor A.M., Jones J., Holly J.M.P., Gaillard R.C., Pralong F.P., Ross R.J.M., Blum W.F., The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers, Journal of Endocrinology, 136, pp. 525-533, (1993)

[99]

Milazzo G., Yip C.C., Maddux B.A., Vigneri R., Goldfine I.D., High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells, Journal of Clinical Investigation, 89, pp. 899-908, (1992)

[100]

Muller H.L., Oh Y., Gargosky S.E., Lehrnbecher T., Hintz R.L., Rosenfeld R.G., Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis, Journal of Clinical Endocrinology and Metabolism, 77, pp. 1113-1119, (1993)

← 5 6 7 8 9 10 11 12 13 14 →